CJC-1295
One of the better-studied growth hormone peptides with actual human trial data backing its effects. The evidence base is solid enough that compounding pharmacies regularly prepare it for clinical use.
Popular among longevity researchers, sports medicine clinicians studying recovery protocols, and endocrinologists investigating growth hormone deficiency treatments.
Since Feb 2026
16 total, 2 human
#5 most researched
What is CJC-1295?
Originally developed as a therapeutic for growth hormone deficiencies, this synthetic peptide has become a cornerstone of growth hormone research. It exists in two distinct variants that offer researchers flexibility in study design—one engineered for week-long activity, another for shorter, more controlled pulses. Clinical researchers and anti-aging specialists frequently turn to CJC-1295 when investigating natural growth hormone enhancement.
This peptide works by binding to the same receptors in the pituitary gland that respond to your body's natural growth hormone-releasing hormone, essentially amplifying the signal to produce more growth hormone. Think of it as turning up the volume on your body's existing growth hormone system rather than introducing foreign hormones directly. The DAC-modified version stays active for days by binding to blood proteins, while the standard version clears within hours, mimicking natural hormone pulses.
What the Research Shows
Relatively strong for a research peptide, with 7 human studies including 3 randomized controlled trials showing consistent dose-dependent effects.
Of 16 total studies identified, 7 were human studies including 3 randomized controlled trials. Key findings from human studies demonstrate that CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-I levels while maintaining normal pulsatile GH secretion patterns and demonstrating a good safety profile.
Notable Studies
Sackmann-Sala L, Ding J, Frohman LA et al. · Growth Horm IGF Res (2009)
RCT · Phase 1 · n=11 · 1 week
Teichman SL, Neale A, Lawrence B et al. · J Clin Endocrinol Metab (2006)
RCT · Phase 128-49 days
Ionescu M, Frohman LA · J Clin Endocrinol Metab (2006)
RCT · Phase 11 week
Pineau T, Schopfer A, Grossrieder L et al. · Forensic Sci Int (2016)
Cohort
Jetté L, Léger R, Thibaudeau K et al. · Endocrinology (2005)
Animal · 72 hours
Reported Benefits
Combinations & Interactions
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.